SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 11:24:56 15/05/2024 pm IST | ||
| 4.3 EUR | -0.46% |
|
| Current month | -1.37% | ||
| 1 month | +8.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 4.3 | -0.46% |
| 14/24/14 | 4.32 | +0.47% |
| 13/24/13 | 4.3 | -0.69% |
| 10/24/10 | 4.33 | -1.14% |
| 09/24/09 | 4.38 | -1.13% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 11:24 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9ZZ1 |
| ISIN | DE000VX9ZZ12 |
| Date issued | 11/04/2022 |
| Strike | 91.36 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.44 € |
|---|---|
| Lowest since issue | 1.13 € |
| Spread | 0.01 € |
| Spread % | 0.23% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- Certificat
